Find Clinical Trial
Efficacy and safety of agomelatine (25-50 mg/day) for 12 weeks in patients with Generalized Anxiety Disorder: a randomised controlled trial
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Neuropsychiatric Diseases |
| Indication | Generalised Anxiety Disorder |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
AGOMELATINE, |
| Active Substance Code | S020098 |
| Protocol Code | CL3-20098-078 |
| ISRCTN Code | ISRCTN75061806 |
Documents and links
| Results summary | READ MORE  |
Quote
| "Picarel F; Zhao JP; Sulaiman AH; Huang YS; Sisrurapanont M; Wei KC; Albarran Severo C; Olivier V; De Bodinat C Eur Psychiatry. 2018; 48(Suppl.):S145-S146" |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
